WATCH LIVE
timothy sykes logo
Seer Inc. Stock Jumps As CEO Buyout Bid And Activists Collide Thumbnail
G Google News

Seer Inc. Stock Jumps As CEO Buyout Bid And Activists Collide

JACK KELLOGG•UPDATED JUL. 6, 2026, 9:18 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Seer Inc. stocks have been trading up by 37.71 percent following highly positive coverage of its latest technological advancements.

Key Takeaways

  • An activist group holding about 7.7% of Seer is urging shareholders to replace the chair/CEO and two directors after a roughly 97% share-price decline, heavy cash burn, and the adoption of a poison pill, arguing for a strategic review to prevent further value destruction.
  • The same activist investors, Bradley Radoff and Michael Torok (Radoff-JEC Group), cite over $465M in cumulative losses, minimal revenue growth, and what they call excessive executive compensation and dilution, and claim the board rejected three premium acquisition offers while only forecasting profitability by 2031.
  • Seer’s chair and CEO, Omid Farokhzad, has submitted an unsolicited, non-binding proposal to take the company private at $2.45 per share in cash plus two contingent value rights, which will be evaluated by an independent special committee with external advisors.
  • Seer successfully preserved broad claims on a core European patent for its particle-based proteomics enrichment technology and prompted a U.S. ITC investigation and related lawsuit against Nanomics over alleged infringement of multiple patents tied to its Proteograph Product Suite.
  • Preliminary data from Seer’s large collaboration with Korea University suggest its Proteograph Product Suite, combined with an ID-free AI framework, can generate deep, reproducible plasma proteomics data that may support future multi-cancer screening across ten major cancer types.

Candlestick Chart

Live Update At 09:18:03 EDT: On Monday, July 06, 2026 Seer Inc. stock [NASDAQ: SEER] is trending up by 37.71%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SEER is a classic battleground between bleeding fundamentals and spicy catalysts. The latest quarterly report shows just $2.79M in revenue, with gross profit under $1M, yet operating expenses near $18.24M. That drove a net loss of about $16.84M and negative EBITDA of roughly $14.53M. For a small-cap life sciences name, that’s a serious burn rate.

On the plus side, SEER’s balance sheet is still thick with cash and securities. The company reports $47.32M in cash and about $166.67M in cash plus short-term investments, versus only $30.65M in total liabilities and $20.38M in long-term debt. Current ratio sits at 17.7, so liquidity is not the immediate problem.

Profitability is. SEER posts brutal margins, with EBIT margin and profit margin deep in the red and returns on equity and assets both more than -20%. The market is clearly discounting that pain: with book value per share near $3.99, the stock trades at roughly half of book and around 7.7x trailing sales.

More Breaking News

The chart reflects that disconnect. Daily closes mostly hugged the $1.70 area until the latest news, then SEER spiked into the low $2s premarket. Intraday, the 5‑minute tape shows steady bids building from about $2.00 to the $2.20–$2.28 zone, signaling traders are now anchoring to deal headlines, not fundamentals alone.

Why Traders Are Locked In On SEER Now

SEER has turned into a live case study in how governance drama, M&A tension, and real technology value collide on the tape.

First, the activist campaign. A 7.7% holder is not small for a micro-cap like Seer Inc. This group, led by Bradley Radoff and Michael Torok, is blasting management for a 97% slide since the 2020 IPO, more than $465M in cumulative losses, and what they describe as rich pay and dilution for weak results. They also claim the SEER board adopted a poison pill and rejected three premium acquisition offers. For traders, that’s the spark for a serious control battle.

Into that fire, SEER’s own chair and CEO, Omid Farokhzad, just lobbed an unsolicited bid to take the company private at $2.45 per share plus two contingent value rights. With the stock recently trading around the low $2s after the news, the market is already handicapping the odds of a bump, a rival bid, or a flat rejection. The special committee of independent directors now reviewing the offer is key; their process will likely drive the next big leg up or down.

At the same time, SEER is not just a shell with cash. The company just defended a major European patent on its particle-based proteomics platform and helped trigger a U.S. ITC investigation and lawsuit against Nanomics over alleged infringement. That strengthens Seer Inc.’s IP moat around its Proteograph Product Suite, which already has promising preliminary data from a Korea University collaboration suggesting potential in multi-cancer screening.

Put together, SEER offers something many event-driven traders love: real technology that might interest strategic buyers, plus activists claiming prior premium offers were turned away, all now colliding with a CEO-led management buyout at a defined price.

Conclusion

SEER is no sleepy biotech anymore; it’s a live battleground where every headline can move the tape. On one side, traders see a company with $166.67M in cash and short-term investments, hard IP wins in Europe, and early data hinting that Proteograph might play in future multi-cancer screening. That’s why strategic value keeps coming up when SEER hits the rumor mill.

On the other side, the numbers do not lie. SEER is burning more than $15M in operating cash per quarter, posting steep negative margins, and forecasting a long road to profitability. Activists say the board already turned down several premium bids and only sees breakeven sometime around 2031. Now those same activists are trying to unseat the chair/CEO and two directors, while that CEO is simultaneously offering $2.45 plus CVRs to take Seer Inc. private.

For active traders, the playbook here is preparation, not prediction. Study the proxy fight, track every filing from the special committee, and map key levels around the buyout price and book value. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.”. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, only your preparation and your discipline.” SEER is offering catalysts; it’s on traders to manage their risk and react, not gamble. This coverage is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”